International Business News - MannKind http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Shares of MannKind Corp. jumped Tuesday as Chief Executive Alfred E. Mann highlighted the potential for the biotechnology company's inhaled insulin system. http://www.ibtimes.com/articles/20080923/mannkind-shares-rise-on-insulin-expectations.htm Tue, 23 Sep 2008 21:36:17 EDT Pfizer Inc. will start switching Exubera inhaled insulin patients to MannKind Corp.'s experimental Technosphere product, which just completed late-stage development. http://www.ibtimes.com/articles/20080916/pfizer-switching-exubera-patients-to-mannkind-drug.htm Tue, 16 Sep 2008 09:37:45 EDT Biotechnology company MannKind Corp. said Tuesday its inhaled insulin system met the main goal of regulating blood-sugar in a late-stage study focusing on Type 1 diabetes patients. http://www.ibtimes.com/articles/20080916/mannkinds-inhaled-insulin-meets-study-goal.htm Tue, 16 Sep 2008 07:31:50 EDT Shares of MannKind Corp. jumped Monday as the biotechnology company prepares a presentation for investors about the late-stage development of its lead product candidate. http://www.ibtimes.com/articles/20080915/mannkind-shares-rise-ahead-of-clinical-trial-data.htm Mon, 15 Sep 2008 18:43:05 EDT Among the earnings stories for Monday, Aug. 11, from AP Financial News: VALENCIA, Calif. (AP)--Biotechnology company MannKind Corp. reported a deeper second-quarter loss, as the company faced higher research and development costs. http://www.ibtimes.com/articles/20080811/earnings-roundup-mannkind-liberty-media.htm Mon, 11 Aug 2008 17:40:56 EDT Biotechnology company MannKind Corp. reported a deeper second-quarter loss, as the company faced higher research and development costs. MannKind reported a loss of $79.8 million, or 79 cents per share, for the second quarter. That compares with a loss of $72 million, or 98 cents per share, in the same quarter last year. http://www.ibtimes.com/articles/20080811/biotech-company-mannkind-corp-sees-wider-2q-loss.htm Mon, 11 Aug 2008 17:26:02 EDT Biotechnology company MannKind Corp. said Monday its first-quarter loss narrowed on lower research and development costs. The company lost $71.4 million, or 70 cents per share, compared with a loss of $73.1 million, or $1 per share, during the same period a year prior. Revenue rose to $20,000 from $10,000. During the most recent period, MannKind had about 28 million additional shares of common stock outstanding. http://www.ibtimes.com/articles/20080505/mannkinds-1q-loss-narrows-on-lower-costs.htm Mon, 05 May 2008 17:23:00 EDT